Triple-negative breast cancer (TNBC) accounts for 10–15% of all breast cancers and is characterized by the lack of expression of the estrogen receptor α (ER-α), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2)1,2. This evidence concerns the gene ERBB2 and breast cancer.